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Abstract: 
Chlamydia trachomatis and Neisseria gonorrhoeae testing guidance recommends extragenital 
screening with locally validated nucleic acid amplification tests, with anatomical sites tested 
separately. Evidence supports multi-patient combined aliquot pooled sampling (PS) for 
population screening; evidence for within-patient PS is sparse. Within-patient PS could be 
more cost-effective for triple-site testing, but requires distinct clinical pathways and 
consideration over loss of information to guide risk assessments and treatment.  We explored 
PS attitudes and practices amongst clinicians in England. A cross-sectional web-based survey 
was distributed to clinical leads of sexual health services throughout England in February 2016. 
Fifty two (52/216, 23%) services responded. One service reported current within-patient PS 
and two were awaiting implementation. Of the 49 services not pooling, five were considering 
implementation. Concerns raised included the inability to distinguish infection site[s] (36/52, 
69%), absence of national guidance (34/52, 65%), and reduced assay performance (18/52, 
34%). Only 8/52 (15%) considered the current level of evidence sufficient to support PS, with 
40/52 (77%) requesting further validation studies, and 39/52 (77%) national guidance. PS was 
rarely used by respondents to this survey, although the response rate was low. The clinical 
challenges presented by PS need to be addressed through further development of the 
evidence base.  
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Introduction 
Increasing pressure on National Health Service (NHS) and public health budgets necessitates 
evaluation of clinical practice to reduce costs without negatively impacting on patient care. 
Pooled sampling (PS) is a potential cost-saving measure that involves testing multiple 
specimens using a single assay with further individual specimen testing only occurring if the 
pooled sample tests positive.1 The potential value of PS for Chlamydia trachomatis (CT) and 
Neisseria gonorrhoeae (NG)  testing using nucleic acid amplification tests (NAATs) has been 
highlighted2, with two possible approaches: Pooling specimens from multiple patients (multi-
patient pooled sampling [MPPS]), or pooling specimens from multiple anatomical sites from 
the same patient (within-patient pooled sampling [WPPS]).  
Although extragenital testing with NAATs is common in routine UK clinical practice, British and 
international guidance suggest caution due to potential issues with test performance and lack 
of manufacturer and regulatory authorisation; they further recommend that anatomical sites 
should be sampled and tested separately.2,3,4,5,6  Only a few studies have evaluated PS in the 
NAAT era, using varied CT/NG testing platforms and sample types, and most focus on MPPS. 
However only one platform to date has a published validation study for the analysis of pooled 
urine samples.7 NAAT performance using MPPS methodologies varies with pool size and site of 
infection8 but similar data do not exist for WPPS methods.9,10  Furthermore, prevalence 
thresholds at which PS can become cost-neutral or cost-saving require consideration of cohort 
heterogeneity, which can be difficult to assess.1,8 
There is currently no British or European guidance on the use of PS for CT/NG testing. With an 
expanding PS evidence base, and currently unknown levels of PS implementation, we aimed to 
establish the prevalence of current and intended PS practice in sexual health services (SHS) in 
England and investigated the barriers and facilitators to its adoption in routine clinical practice. 
 
 
  
 
 
 
 
 
History taking 
and sample 
site selection
Sampling Laboratory testing Results reporting Follow up
[Standard of care]
Single, dual, 
triple site
Women – swab[s] 
taken from appropriate 
sites 
Men – first catch urine 
and/or swab[s] taken 
from appropriate sites 
Samples sent individually 
NAAT assays processed 
individually by local lab
POSITIVES: Results reported by 
infection and specific site
Coded by clinics and reported to PHE
•NEGATIVES: Patient 
informed all tests 
negative
POSITIVES: Patient attends 
for treatment
Patient informed of specific 
site of infection and chance 
of microbiological cure
Need for TOC determined 
[Multi-patient PS]
Single (genital) 
site 
Women – vulvovaginal 
swab
Men – first catch urine 
Samples pooled from 
multiple patients into a 
single aliquot
Pools testing POSITIVE will 
need to have individual 
source samples re-tested
POSITIVES: Results reported by site 
(urine or VVS) and infection
Coded by clinics and reported to PHE
•NEGATIVES: Patient 
informed all tests 
negative
POSITIVES: Patient attends 
for treatment
Patient informed of specific 
site of infection and chance 
of microbiological cure
Need for TOC determined 
[Within-patient PS]
Dual or triple 
site 
Women – swab[s] 
taken from 
appropriate sites 
Men – first catch urine 
and/or swab[s] taken 
from appropriate sites
Samples combined in the GU 
service and sent as single 
combined aliquot 
NAAT assays processed by 
local lab
POSITIVES: Results reported by 
infection but not by specific site
Coded by clinics but not reported 
to PHE initially
•NEGATIVES: Patient 
informed all tests 
negative
Patient attends for treatment 
Individual sites are re-sampled to 
establish sites of infection
Once specific sites of infection are 
known casenotes are re-coded 
and reported to PHE 
If TOCs are required this can be 
taken from specific affected sites
Figure 1: Comparison of theoretical PS pathways with current standard of care 
Methods 
We designed and distributed a web-based survey to explore attitudes and practices relating to 
PS among sexual health clinicians in England [Appendix]. Survey questions were devised to 
include key aspects of the evidence base identified from an initial literature review. 
Participants were asked about advantages and disadvantages of expanding PS within clinical 
practice, including consideration of the quality of current evidence and clinical guidance. 
Participants were presented with answer grids containing lists of possible responses identified 
in the literature, with some options for clarifications in free text. The survey was piloted by the 
authors and genitourinary medicine clinical specialist trainees, and revised following feedback. 
A link to the survey was sent to the clinical leads of SHS in England. Participants were identified 
in contact lists for surveillance reporting to Public Health England (PHE) and through British 
Association of Sexual Health & HIV (BASHH) regional trainee representatives. Survey 
dissemination was supported by these established clinical networks and regional BASHH 
trainee representatives. The survey was run between 11/02/16 and 21/05/16, with a reminder 
email sent on 02/03/16 and a reminder message published in BASHH newsletter on 31/03/16. 
Survey responses were analysed using Microsoft Excel. Partially completed survey responses 
were excluded from the analysis. 
 
 
Results 
In total, 52/216 (23.3%) services returned complete responses to the survey. Seventeen 
incomplete and four duplicate responses were excluded from the analysis. Responses were 
received from all PHE regions apart from the East Midlands. 
 
Table 1: Location in England of sexual health service clinical leads who responded to this 
online survey of current implementation and prospective viewpoints of pooled sampling  
Clinic Location N % 
East Midlands 0/12 0 
East of England 3/22 13. 6 
London 13/34 38.2 
North East 4/14 28. 6 
North West 11/35 31.4 
South East 
8/33 
24.2 
South West 8/25 32.0 
West Midlands 1/20 5.0 
Yorkshire & the Humber 4/21 19.0 
Total 52  
 
 
Current or considered use of PS 
One service reported current WPPS and two were awaiting imminent implementation of PS. Of 
the 49 services not pooling, five were considering implementation. Services with PS 
experience, or plans to implement PS, were introducing PS to facilitate cost-saving (3/3) and to 
be innovative (3/3), with 2/3 introducing PS as part of clinical research assessing PS. The single 
service which had introduced WPPS found benefits of cost-saving and increased clinic capacity, 
but experienced challenges with patient acceptability and a lack of national PS guidance. 
 
Prospective view of PS 
Of the 49 services without current or imminent PS activity, 15 (31%) were expecting PS to 
become future standard practice in SHS. The key benefit of PS identified by services was the 
potential for cost-saving (41/49, 84%), with a smaller proportion looking to increase clinic 
capacity (9/49, 18%). Opportunities for innovation (12/49, 25%) and clinical research (11/49, 
22%) were also identified. 
 
 
Barriers to the wider implementation of PS 
All respondents, regardless of PS experience, were asked about the negative aspects and 
perceived barriers to wider PS implementation. Commonly reported barriers to the wider 
implementation of PS were: loss of infection site information (36/52, 69%), absence of national 
guidance (34/52, 65%), lack of supportive evidence (21/52, 40%) and reduced assay 
sensitivity/specificity (18/52, 35%). 
 
Current PS evidence base 
Only 8/52 (15%) respondents considered the existing evidence sufficient to support PS, with 
40/52 (77%) requesting further validation studies, 39/52 (77%) national guidance, and 25/52 
(48%) more cost effectiveness data. 
Table 2: Online survey of current implementation and prospective viewpoints of pooled 
sampling methods for CT/NG NAATs completed by clinical leads of sexual health services in 
England between 11th February and 21st March 2016 
Response N % 
What would you consider to be potential positive aspects of 
introducing pooled sampling within your service? 
49 94.2 
Potential for cost savings 41 83.7 
Anticipation of future changes in practice 15 30.6 
Innovation 12 24.5 
Involvement in research 11 22.4 
Increase clinic capacity 9 18.4 
I see no benefits 2 4.1 
Patient satisfaction 1 2.0 
What do you believe to be the barriers to the wider 
implementation of pooled sampling? 
52 100 
Impact on clinical care   
Concern over not knowing anatomical sites of infection 36 69.2 
Negative effects on patient care 7 13.5 
Laboratory and test aspects   
Decrease in assay sensitivity/specificity 18 34.6 
Increase in inhibitory results 17 32.7 
Challenges with local laboratory validation 15 28.8 
Guidance and evidence   
Absence of national guidance or testing policy 34 65.4 
Not enough supportive evidence 21 40.4 
Service issues   
Other priorities within services 8 15.4 
Influence of high local STI prevalence on cost effectiveness 4 7.7 
Cost implications 3 5.8 
Time required to make the change 3 5.8 
Local commissioning policy 2 3.8 
Other   
I do not foresee any barriers 1 1.9 
Which aspects of pooled sampling would you like more 
research or guidance to focus on? 52 100 
Validation of the sensitivity and specificity of pooled sampling 40 76.9 
Clinical guidelines on pooled sampling 39 75.0 
Opinion from BASHH on the utilisation of pooled sampling 38 73.1 
Cost effectiveness data 25 48.1 
Clinical research on the implementation of pooled sampling 18 34.6 
Discussion 
To our knowledge, this is the first survey to assess current practice and opinion on the 
utilisation of MPPS or WPPS for CT/NG NAATs within sexual health services. We have 
established that the use of PS is uncommon but almost a third of services responding to the 
survey expected PS to become standard practice, highlighting the need for a robust evidence 
base and national guidance. The key driver for PS introduction was the potential for cost-
saving. The majority of respondents expressed concerns about the wider implementation of PS 
from clinical and laboratory standpoints, underpinned by a lack of supportive evidence.  
 
Despite concerted efforts to engage SHS, the response rate was low, which influences the 
representativeness of the findings. Clinicians may have been more likely to respond if they had 
an interest in PS, or were considering introducing it. Conversely others may have opted not to 
respond if they felt they had insufficient knowledge to answer accurately. Our study may 
therefore overestimate the proportion anticipating PS to become standard practice. However 
survey responses were from geographically diverse locations across England. The survey 
content was informed by the existing evidence base and highlights concerns to inform future 
research. 
 
Competitive re-tendering of SHS in England is encouraging novel approaches to find 
efficiencies within existing clinical pathways. Studies from Australia and Lithuania examining 
MPPS have reported potential cost savings of between 39%11 and 70%12, although modelling 
suggests that savings may be more limited with increasing prevalence of chlamydia and 
inhibitors of PCR.13 Whilst financial considerations are important, this should not be at the 
detriment of the patient experience and outcomes, nor public health. No qualitative data are 
available regarding patients’ opinions on WPPS, and the single site who had implemented PS in 
our survey found that challenges with patient acceptability were encountered. Consideration 
must be given to re-sampling individual anatomical sites in patients testing positive from WPPS 
to ensure the identification of extragenital infections. Whilst not influencing treatment choice 
directly according to current clinical guidance, re-sampling provides accurate monitoring of 
transmission dynamics. Knowledge of specific infection sites informs not only individual risk 
reduction advice, but collectively informs public health surveillance data around risk 
behaviours associated with STI acquisition.14 Treatment choice for any positive CT result which 
included a rectal sample should also ensure adequate therapy with doxycycline.3 With 
widespread antimicrobial resistance amongst NG populations it is important to ensure that PS 
does not hinder NG culture or test of cure pathways.   
Within our survey, clinicians expressed concerns about a potential decrease in NAAT 
performance using PS. Caution with regards to the sensitivity/specificity of NAATs for WPPS 
seems appropriate with existing studies showing mixed results: one study found a superior 
sensitivity of WPPS for identifying CT infection than vulvovaginal sampling alone9, whilst 
another demonstrated inferior sensitivity amongst triple-site samples in men-who-have-sex-
with-men (MSM)10, 15. The potential effect of inhibitors on PS validity is also of some concern. 
There are no studies reviewing the effect of inhibitors on WPPS methods, and studies on MPPS 
have conflicting findings.11,16 These concerns could eventually be mitigated by developing PS 
methods and ensuring rigorous local laboratory validation. PS requires new laboratory 
processes for combining NAAT samples prior to assay testing, which need to consider handling, 
mixing and potential contamination of combining samples, as well as storing individual 
samples for re-testing if required. However if equivalence to standards of care can be shown 
for WPPS, then the inclusion of extragenital specimens for patients who would previously only 
have been tested genitally could increase identification and treatment of CT/NG infections.  
With the vast majority of clinicians feeling the current evidence base insufficient to confidently 
support PS it is clear that significant unanswered questions remain. SHS considering 
implementation of MPPS are likely to find an existing example of practice to base service 
change upon. WPPS is not a widely validated technique on many current commercial NAAT 
platforms. The practical implementation of any new sampling methodology is likely to 
generate challenges and we would welcome more data on services’ experience with PS 
implementation. Further data assessing WPPS assay performance and cost-effectiveness are 
required.  
 
The current financial pressures within sexual health services in England are encouraging 
services to innovate to maintain standards of care with increasingly smaller budgets. We found 
that pooling of samples was uncommon among survey respondents. However, several services 
were considering implementing pooling and the majority of respondents saw potential cost 
savings of pooling as a positive feature. Considered debate regarding the level of influence that 
cost should have on clinical care needs to continue, and with PS this needs to recognize that 
with infinite resources separate site NAAT testing would remain gold standard practice. 
Further evidence and guidance from professional bodies would be helpful for clinicians and 
service commissioners  
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Appendix 1: Web-based survey 
Many thanks for taking the time to complete this survey. It should take between 5 and 10 
minutes to complete. A response is required for all questions marked with a red asterisk. 
The survey explores current and planned activity in relation to pooling of Chlamydia 
trachomatis (CT) / Neisseria gonorrhoeae (NG) nucleic acid amplification test (NAAT) samples. 
This pooling may include, for example: 
- pooled aliquots of multiple urine samples in the laboratory prior to assay testing 
- multi-site swab samples for the same patient being collated and tested as a single aliquot 
This survey is being done as part of the BASHH/ PHE Fellowship by Dr Jonathan Shaw, 
supervised by Drs Gwenda Hughes and John Saunders at Public Health England. 
All responses will be anonymised and confidential. If you have any questions please contact 
jonathan.shaw@phe.gov.uk 
 
1. In which region is your clinic situated? 
a. East Midlands 
b. East of England 
c. London 
d. North East 
e. North West 
f. South East 
g. South West  
h. West Midlands 
i. Yorkshire & the Humber 
 
2. At which site is your clinic located? 
 
3. Do you, or have you previously, pooled samples within your service? 
a. Yes 
b. No, but we are planning to 
c. No 
 
For services answering “Yes” to Q3: 
 In which patient group(s) do you, or have you, pooled samples within your service? 
(please select all that apply) 
 
 Asymptomatic Symptomatic Contacts of 
infections 
Men who have sex 
with women only 
   
Men who have sex 
with men 
   
Women who have 
sex with men 
   
Women who have 
sex with women 
only 
   
 
 Taking an example patient who requires triple-site testing in clinic, which of the 
following samples would you pool together in your service? 
(Please only complete rows for patient groups that you currently pool or have pooled with) 
 
 Urine Genital swab Pharyngeal 
swab 
Rectal swab 
Men who 
have sex with 
men 
    
Women who 
have sex with 
men 
    
Women who 
have sex with 
women only 
    
 
 Would you be willing to share your clinic's pooled sampling protocol and/or be contacted 
to discuss it? 
o Yes 
o No 
o We do not have a clinic protocol on pooled sampling 
 
 When did pooling of samples commence in your service? 
 
 Why did you introduce pooled sampling within your service?(please select all that apply) 
o Cost saving  
o Innovation  
o Anticipation of future changes in practice  
o Research    
o Patient satisfaction  
o Increase clinic capacity  
o Other, please specify (free text) 
 
 Did you perform a local validation study on your pooled samples? 
o Yes 
o No 
o Unsure 
 
 Have you discontinued pooled sampling? 
o Yes 
 When did you discontinue pooling of samples in your service? 
 Why did you discontinue pooling in your service? 
 Decrease in assay sensitivity/specificity 
 Inhibitors affecting assay performance 
 Challenges with local laboratory validation 
 Cost implications 
 Influence of high local STI prevalence on cost effectiveness 
 Concern over not knowing anatomical sites of infection 
 Negative effects on patient care 
 Patient acceptability 
 Time required to make the change 
 Local commissioning policy 
 Not enough supportive evidence 
 Absence of national guidance or testing policy 
 Completion of a research study 
o No 
 
 In patients who test CT/NG positive on a pooled sample do you re-test individual sites 
before treatment to ascertain patients' specific site[s] of infection? 
(please select all that apply) 
o No 
o Yes if CT monoinfection 
o Yes if NG monoinfection 
o Yes if CT/NG dual infection 
 
 Would you wait for the specific site of infection to be identified before issuing treatment? 
o Yes 
o No 
 
 Have you performed an evaluation of pooled sampling since introducing it into practice 
within your service? 
o Yes 
 If yes, what have you evaluated? 
 Impact on assay sensitivity/specificity 
 Inhibitors affecting assay performance 
 Laboratory costs 
 Influence of local STI prevalence on cost effectiveness 
 Treatment choice 
 Treatment costs 
 Patient acceptability 
 Staff costs 
o No 
o Unsure 
 
 Did you experience any of the following challenges when implementing pooled 
sampling?(please select all that apply) 
o Decrease in assay sensitivity/specificity 
o Inhibitors affecting assay performance 
o Challenges with local laboratory validation 
o Cost implications 
o Influence of high local STI prevalence on cost effectiveness 
o Concern over not knowing anatomical sites of infection 
o Negative effects on patient care 
o Patient acceptability 
o Time required to make the change 
o Local commissioning policy 
o Not enough supportive evidence 
o Absence of national guidance or testing policy 
o None of the above 
o Other, please specify (free text) 
 
 Did you find any benefits from introducing pooled sampling within your service?(please 
select all that apply) 
o Cost saving  
o Innovation  
o Anticipation of future changes in practice  
o Research    
o Patient satisfaction  
o Increase clinic capacity  
o None of the above 
o Other, please specify (free text) 
 
 Have you been involved, or are you currently involved, in clinical research with pooled 
sampling? 
o Yes, we are currently involved  
o Yes, we have previously been involved    
o No, but we are currently planning research  
o No  
o Unsure 
 
For services answering “No, but we are planning to” to Q3: 
 When do you anticipate that pooling of samples will commence in your service? 
 
 Have you generated a testing protocol for pooling samples? 
o Yes 
 Would you be willing to share this with us?  
 Yes 
 No 
o This is in progress 
o No 
 
 Which patient group(s) will be eligible for pooled sampling within your service?(please 
select all that apply) 
 Asymptomatic Symptomatic Contacts of 
infections 
Men who have sex 
with women only 
   
Men who have sex 
with men 
   
Women who have 
sex with men 
   
Women who have 
sex with women 
only 
   
 
 How are you considering pooling your samples?(please select all that apply) 
o Pooled urine aliquots (multiple samples from more than one patient) 
o Pooling swabs from genital and extragenital sites (from a single patient) 
o Pooling extragenital swabs with a first catch urine (from a single patient) 
o Pooling only extragenital swabs (from a single patient) 
o Other, please specify (free text) 
 
 Why are you considering introducing pooled sampling within your service?(please select all 
that apply) 
o Cost saving  
o Innovation  
o Anticipation of future changes in practice  
o Research    
o Patient satisfaction  
o Increase clinic capacity  
o Other, please specify (free text) 
 
 Do you have any concerns about introducing pooled sampling in your service?(please 
select all that apply) 
o Decrease in assay sensitivity/specificity 
o Inhibitors affecting assay performance 
o Challenges with local laboratory validation 
o Cost implications 
o Influence of high local STI prevalence on cost effectiveness 
o Concern over not knowing anatomical sites of infection 
o Negative effects on patient care 
o Patient acceptability 
o Time required to make the change 
o Local commissioning policy 
o Not enough supportive evidence 
o Absence of national guidance or testing policy 
o No 
o Other, please specify (free text) 
 
For services answering “No” to Q3: 
 Are you considering a future introduction of pooled sampling within your service? 
o Yes 
o No 
o Don't know 
 
 Do you have any reservations regarding the introduction of pooled sampling within your 
service? (please select all that apply)      
  
o Decrease in assay sensitivity/specificity 
o Inhibitors affecting assay performance 
o Challenges with local laboratory validation 
o Cost implications 
o Influence of high local STI prevalence on cost effectiveness 
o Concern over not knowing anatomical sites of infection 
o Negative effects on patient care 
o Patient acceptability 
o Time required to make the change 
o Local commissioning policy 
o Not enough supportive evidence 
o Absence of national guidance or testing policy 
o We have other priorities within the service 
o No 
o Other, please specify (free text) 
 
 What would you consider to be potential positive aspects of introducing pooled sampling 
within your service?(please select all that apply) 
o Cost saving  
o Innovation  
o Anticipation of future changes in practice  
o Research    
o Patient satisfaction  
o Increase clinic capacity  
o I see no benefits 
o Other, please specify (free text) 
All respondents: 
4. What do you believe to be the barriers to the wider implementation of pooled 
sampling?(please select all that apply)      
  
o Decrease in assay sensitivity/specificity 
o Inhibitors affecting assay performance 
o Challenges with local laboratory validation 
o Cost implications 
o Influence of high local STI prevalence on cost effectiveness 
o Concern over not knowing anatomical sites of infection 
o Negative effects on patient care 
o Not enough supportive evidence 
o Time required to make the change 
o Local commissioning policy 
o Absence of national guidance or testing policy 
o Other priorities within services 
o I do not forsee any barriers 
o Other, please specify (free text) 
 
5. In your opinion does the evidence you have reviewed support the use of pooled sampling 
in GU services? 
o Yes 
o No 
o Unsure 
o I am not familiar with the evidence 
 
6. Which aspects of pooled sampling would you like more research or guidance to focus 
on?(please select all that apply)   
o Cost effectiveness data 
o Validation of the sensitivity and specificity of pooled sampling 
o Clinical research on the implementation of pooled sampling 
o Clinical guidelines on pooled sampling 
o Opinion from BASHH on the utilisation of pooled sampling 
o I don’t think further research/guidance is required 
o Other, please specify (free text)  
 
Thank you very much for giving your time to complete this survey. 
All responses will be anonymised and confidential. If you have any questions please contact 
jonathan.shaw@phe.gov.uk 
 
Would you be willing to be contacted as part of discussions regarding the development of best 
practice pooled sampling guidance? 
o Yes (please provide a contact email) 
o No 
 
